These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22771002)

  • 1. A community-based survey of varicella-zoster virus-specific immune responses in the elderly.
    Tang H; Moriishi E; Okamoto S; Okuno Y; Iso H; Asada H; Yamanishi K; Mori Y;
    J Clin Virol; 2012 Sep; 55(1):46-50. PubMed ID: 22771002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An inverse correlation of VZV skin-test reaction, but not antibody, with severity of herpes zoster skin symptoms and zoster-associated pain.
    Asada H; Nagayama K; Okazaki A; Mori Y; Okuno Y; Takao Y; Miyazaki Y; Onishi F; Okeda M; Yano S; Kumihashi H; Gomi Y; Maeda K; Ishikawa T; Iso H; Yamanishi K;
    J Dermatol Sci; 2013 Mar; 69(3):243-9. PubMed ID: 23183011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-gamma enzyme-linked immunospot assay.
    Sadaoka K; Okamoto S; Gomi Y; Tanimoto T; Ishikawa T; Yoshikawa T; Asano Y; Yamanishi K; Mori Y
    J Infect Dis; 2008 Nov; 198(9):1327-33. PubMed ID: 18774884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine.
    Levin MJ; Smith JG; Kaufhold RM; Barber D; Hayward AR; Chan CY; Chan IS; Li DJ; Wang W; Keller PM; Shaw A; Silber JL; Schlienger K; Chalikonda I; Vessey SJ; Caulfield MJ
    J Infect Dis; 2003 Nov; 188(9):1336-44. PubMed ID: 14593591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, humoral and cell-mediated immune responses to herpes zoster vaccine in subjects with diabetes mellitus.
    Hata A; Inoue F; Yamasaki M; Fujikawa J; Kawasaki Y; Hamamoto Y; Honjo S; Moriishi E; Mori Y; Koshiyama H
    J Infect; 2013 Sep; 67(3):215-9. PubMed ID: 23603250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial.
    Hata A; Inoue F; Hamamoto Y; Yamasaki M; Fujikawa J; Kawahara H; Kawasaki Y; Honjo S; Koshiyama H; Moriishi E; Mori Y; Ohkubo T
    Diabet Med; 2016 Aug; 33(8):1094-101. PubMed ID: 26605507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Varicella-zoster virus-specific cell-mediated immunity in subjects with herpes zoster.
    Otani N; Yamanishi K; Sakaguchi Y; Imai Y; Shima M; Okuno T
    J Immunol Methods; 2012 Mar; 377(1-2):53-5. PubMed ID: 22261191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased incidence of herpes zoster in patients on renal replacement therapy cannot be explained by intrinsic defects of cellular or humoral immunity to varicella-zoster virus.
    Rondaan C; de Joode AAE; van Assen S; Bos NA; Westerhuis R; Westra J
    Antiviral Res; 2018 Oct; 158():206-212. PubMed ID: 30102958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.
    Levin MJ; Schmader KE; Pang L; Williams-Diaz A; Zerbe G; Canniff J; Johnson MJ; Caldas Y; Cho A; Lang N; Su SC; Parrino J; Popmihajlov Z; Weinberg A
    J Infect Dis; 2016 Jan; 213(1):14-22. PubMed ID: 26452397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between cell-mediated immunity to Varicella-Zoster virus and aging in subjects from the community-based Shozu Herpes Zoster study.
    Shirane R; Tang H; Hayashi K; Okuno Y; Iso H; Asada H; Yamanishi K; Mori Y;
    J Med Virol; 2017 Feb; 89(2):313-317. PubMed ID: 27420414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major depressive disorder and immunity to varicella-zoster virus in the elderly.
    Irwin MR; Levin MJ; Carrillo C; Olmstead R; Lucko A; Lang N; Caulfield MJ; Weinberg A; Chan IS; Clair J; Smith JG; Marchese RD; Williams HM; Beck DJ; McCook PT; Johnson G; Oxman MN
    Brain Behav Immun; 2011 May; 25(4):759-66. PubMed ID: 21329753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered cellular and humoral immunity to varicella-zoster virus in patients with autoimmune diseases.
    Rondaan C; de Haan A; Horst G; Hempel JC; van Leer C; Bos NA; van Assen S; Bijl M; Westra J
    Arthritis Rheumatol; 2014 Nov; 66(11):3122-8. PubMed ID: 25223407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VZV skin-test reaction, but not antibody, is an important predictive factor for postherpetic neuralgia.
    Imoto K; Okazaki A; Onishi F; Miyazaki Y; Okeda M; Yano S; Takao Y; Gomi Y; Ishikawa T; Okuno Y; Mori Y; Iso H; Yamanishi K; Asada H;
    J Dermatol Sci; 2015 Sep; 79(3):235-40. PubMed ID: 26070505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of varicella zoster virus-specific cell-mediated immunity by using an interferon-γ enzyme-linked immunosorbent assay.
    Hayashida K; Ozaki T; Nishimura N; Gotoh K; Funahashi K; Nakane K; Gomi Y; Manabe S; Ishikawa T; Yamanishi K
    J Immunol Methods; 2015 Nov; 426():50-5. PubMed ID: 26232696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age.
    Vermeulen JN; Lange JM; Tyring SK; Peters PH; Nunez M; Poland G; Levin MJ; Freeman C; Chalikonda I; Li J; Smith JG; Caulfield MJ; Stek JE; Chan IS; Vessey R; Schödel FP; Annunziato PW; Schlienger K; Silber JL
    Vaccine; 2012 Jan; 30(5):904-10. PubMed ID: 22154769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered phenotype and functionality of varicella zoster virus-specific cellular immunity in individuals with active infection.
    Schub D; Janssen E; Leyking S; Sester U; Assmann G; Hennes P; Smola S; Vogt T; Rohrer T; Sester M; Schmidt T
    J Infect Dis; 2015 Feb; 211(4):600-12. PubMed ID: 25180236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility to varicella-zoster virus in Thai children and young adults.
    Kositanont U; Wasi C; Oonsombat P; Suvatte V; Thongcharoen P
    Southeast Asian J Trop Med Public Health; 1985 Sep; 16(3):414-20. PubMed ID: 3006266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine.
    Weinberg A; Zhang JH; Oxman MN; Johnson GR; Hayward AR; Caulfield MJ; Irwin MR; Clair J; Smith JG; Stanley H; Marchese RD; Harbecke R; Williams HM; Chan IS; Arbeit RD; Gershon AA; Schödel F; Morrison VA; Kauffman CA; Straus SE; Schmader KE; Davis LE; Levin MJ;
    J Infect Dis; 2009 Oct; 200(7):1068-77. PubMed ID: 19712037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Varicella-zoster virus-specific cell-mediated immune responses in HIV-infected adults.
    De Castro N; Carmagnat M; Kernéis S; Scieux C; Rabian C; Molina JM
    AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1089-97. PubMed ID: 21417759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation.
    Distler E; Schnürer E; Wagner E; von Auer C; Plachter B; Wehler D; Huber C; Kolbe K; Meyer RG; Herr W
    Biol Blood Marrow Transplant; 2008 Dec; 14(12):1417-24. PubMed ID: 19041065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.